Petefészekrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BRCA1 20
• BRCA2 13
• PARP 27
• TP53 6
• PD-1 12
• AKT 2
• HER2 16
• PD-L1 7
• PI3K 3
• STAT3 1
• mTOR 0
• VEGF 7
• KRAS 6
• EGFR 3
• PTEN 2
• MAPK 0
• CTNNB1 0
• FAK 1
• MYC 0
• NRF2 0
• CTLA-4 6
• ERK 1
• JAK 0
• STING 0
• GPX4 0
• HIF-1 0
• MEK 1
• TROP2 4
• PALB2 5
• B7-H3 7
• CDK4/6 4
• ATM 1
• CD47 0
• IL-6 0
• PIK3CA 3
• EZH2 1
• JNK 0
• YAP 0
• BCL-2 0
• BRAF 4
• CXCR4 0
• HDAC 0
• PPAR 0
• AMPK 0
• ARID1A 3
• AXL 1
• COX-2 2
• NMDA 0
• TIGIT 0
• AR 0
• CD40 1
• HER3 1
• HMGB1 0
• KEAP1 1
• METTL3 0
• RAS 0
• TLR4 0
• FGFR 0
• PINK1 0
• PKM2 0

45+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  The role of p16 expression in sensitivity and resistance to CDK2 inhibitors

  University of Colorado· Boulder, Egyesült Államok· 43 146 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, Egyesült Államok· 390 447 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Immune Dysfunction, Social Determinants of Health, and Ovarian Cancer Outcome Differences

  University of Pittsburgh at Pittsburgh· Pittsburgh, Egyesült Államok· 674 142 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NICHD · R61

  Ultrasound-guided Ovarian Tissue Graft generation Platform to improve fertility outcomes

  Atera Medical· Mountain View, Egyesült Államok· 377 257 USD awarded in fiscal year 2026· until 2028. jún.

• NIH NCI · R44

  Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer

  Trevarx Biomedical, Inc.· Philadelphia, Egyesült Államok· 1 174 824 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding the Lipidome of Adipose-Derived Extracellular Vesicles in Ovarian Cancer: Mechanistic Insight into Tumor-Adipose Crosstalk (Lipid-Ex)

  Philipps Universitaet Marburg· Marburg, Németország· EU contribution 202 125 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Precision Reasoning In Multimodal Ovarian cancer (PRIMO)

  Institut Regional du Cancer de Montpellier· Montpellier Cedex 5, Franciaország· EU contribution 150 000 EUR· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  CAR T ceLls with Anti-exhaUstion Device for Immunotherapy Advancement (CLAUDIA)

  Fondazione Istituto Italiano di Tecnologia· Genova, Olaszország· EU contribution 150 000 EUR· until 2028. márc.

• European Commission (Horizon Europe) · HORIZON-EIC

  Interpretable Multimodal Predictive Agents and Digital Twins for Ovarian Cancer (IMPACT-OC)

  Danube Private University Gmbh· Krems-Stein, Ausztria· EU contribution 3 977 586 EUR· until 2030. szept.· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A Novel Phase-2a Clinical Trial for a Next-Generation Oncolytic Immunotherapy Targeting Platinum-Resistant Ovarian Cancer (OCTOPOD-Ph2a)

  Theolytics Ltd· Oxford, Egyesült Királyság· EU contribution 7 998 791 EUR· until 2029. máj.· 3 countries

10 of 659 running projects, newest first. Listed amounts together: 367,4 M USD + 54,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Frissítve: 2026. szept. 22.

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of PF-06873600 in People With Cancer

  NCT03519178· Pfizer· Frissítve: 2025. nov. 14.

  “Per business decision, but not due to safety concerns or regulatory request.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

  NCT04585958· National Cancer Institute (NCI)· Forrás

• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Jazz Pharmaceuticals· Forrás

• A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

  NCT04482309· AstraZeneca· Forrás

• Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Daiichi Sankyo· Forrás

• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Daiichi Sankyo· Forrás

• DESTINY-PANTUMOUR04

  NCT07124000· AstraZeneca· Forrás

• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

  NCT06003231· Seagen, a wholly owned subsidiary of Pfizer· Forrás

• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

  NCT04421963· AstraZeneca· Forrás

• ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

  NCT06973161· AstraZeneca· Forrás

• A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

  NCT04639219· AstraZeneca· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 48
• Organoids 19
• Mendelian Randomization Analysis 30
• CRISPR-Cas Systems 15
• Gene Expression Profiling 126
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 6
• Exome Sequencing 11
• Proteomics 62
• Metabolomics 17
• Mass Spectrometry 6
• Flow Cytometry 26
• Immunohistochemistry 95
• Liquid Biopsy 15
• Circulating Tumor DNA 14
• Xenograft Model Antitumor Assays 234
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 57
• Machine Learning 60
• Deep Learning 36
• Cohort Studies 105
• Genome-Wide Association Study 27

• [Oncogenetics and molecular tumor boards in private practice: Specificities and perspectives].

  Bull Cancer, 2026. szept.

• Beyond CA-125: circulating cell-free DNA as the next-generation biomarker in ovarian malignancy.

  BMC Cancer, 2026. szept.

• Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib.

  JCO Precis Oncol, 2026. aug.

• Pamiparib plus surufatinib with ctDNA monitoring in platinum-resistant ovarian cancer after PARP inhibitor progression: a phase Ib/II trial (POST-PARPi).

  BMC Med, 2026. aug.

• Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer.

  Cancer Med, 2026. aug.

• Circulating Tumor DNA in Tracking Minimal Residual Disease and Recurrence in Ovarian Cancer: A Retrospective Cohort.

  Cancer Invest, 2026. máj.

• Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

  Int J Mol Sci, 2026. ápr.

• Prognostic value of circulating tumor DNA for minimal residual disease detection in ovarian cancer: A systematic review and meta-analysis.

  Crit Rev Oncol Hematol, 2026. márc.

• ctDNA monitoring using tumor-informed copy number analysis.

  EMBO Mol Med, 2026. márc.

• Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

  ESMO Open, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.